Dronabinol for Anterior Cruciate Ligament Tear

Phase-Based Progress Estimates
Northwestern University Feinberg School of Medicine, Chicago, IL
Anterior Cruciate Ligament Tear+12 More
Dronabinol - Drug
All Sexes
What conditions do you have?

Study Summary

The purpose of the proposed study is to evaluate the efficacy of dronabinol for postoperative pain after arthroscopic surgery of the knee. The investigators hypothesize that dronabinol will relieve pain, reduce opioid consumption and will result in few negative side effects. If this pilot study shows promising results the investigators will expand the trial to include additional arthroscopic surgeries (hip, shoulder) and other types of orthopaedic surgery.

Eligible Conditions

  • Anterior Cruciate Ligament Tear
  • Osteoarthritis of the Knee
  • Chondral Injury of Right Knee
  • Meniscus Tears
  • Ligament Knee Injury
  • Knee Injuries
  • Synovitis of Knee
  • Loose Body Knee
  • Chondral Injury of Left Knee

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Other trials for Anterior Cruciate Ligament Tear

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: up to 21 days post-surgery

Day 21
PROMIS Bank v2.0 - Pain Behavior
PROMIS Bank v2.0 - Physical Function
Patient-Reported Outcomes Measurement Information System (PROMIS) Bank v1.1 - Pain Interference
Day 7
Opioid consumption
Pain Visual Analog Scale (VAS)

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Anterior Cruciate Ligament Tear

Trial Design

2 Treatment Groups

1 of 2
1 of 2
Experimental Treatment
Non-Treatment Group

30 Total Participants · 2 Treatment Groups

Primary Treatment: Dronabinol · Has Placebo Group · Phase 3

Experimental Group · 1 Intervention: Dronabinol · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 21 days post-surgery

Trial Background

Prof. Vehniah Tjong, Assistant Professor
Principal Investigator
Northwestern University
Closest Location: Northwestern University Feinberg School of Medicine · Chicago, IL
Photo of Chicago  1Photo of Chicago  2Photo of Chicago  3
2011First Recorded Clinical Trial
1 TrialsResearching Anterior Cruciate Ligament Tear
142 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.